CONNECT WITH US
HealthTech

HealthTech

GE HealthCare to acquire Sofie Biosciences for $945M

MedTech Dive logo

Published on

Add as a preferred source on Google
GE HealthCare to acquire Sofie Biosciences for $945M

Sofie Biosciences is expected to expand GE HealthCare’s footprint in the radiopharmaceutical industry, helping manufacture and distribute time-sensitive drugs used in PET imaging.

Sofie Biosciences will become part of GE HealthCare’s pharmaceutical diagnostics business, PDx, when the deal closes, which is expected in the first half of 2027.

GE HealthCare said it will continue to expand access to its existing proprietary F18 radiopharmaceutical products and advance a pipeline of new products, both through Sofie Biosciences and PDx’s other CMO partners across the U.S.

Sofie Biosciences, meanwhile, will remain an independent manufacturing partner to its customers and supply its existing portfolio, including products from other radiopharmaceutical providers. Sofie Biosciences has a U.S. network of 15 CMO sites.

BTIG’s Zimmerman said the added manufacturing and distribution capacity could help reduce bottlenecks in the radiopharmaceutical adoption cycle.

GE HealthCare will also gain U.S. rights to FAPI-74, a pipeline pan-cancer PET radiotracer for which it holds rights outside the U.S.

“As part of GE HealthCare, Sofie Biosciences is expected to grow in the low double digits, and enables us to participate across the radiopharmaceutical value stream, meeting customer demand through a mix of GE HealthCare owned and partner facilities,” Kevin O'Neill, CEO of GE HealthCare’s PDx business, said in a statement.

The acquisition is expected to contribute to GE HealthCare’s revenue growth and adjusted earnings per share in the first full year of ownership, the company said.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.